Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
Sponsor content
359 result(s) found, displaying 1 to 10
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KEYTRUDA SC pembrolizumab 395 mg/ 2.4 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KEYTRUDA SC pembrolizumab 790 mg/ 4.8 mL solution for injection vial.
-
Australian Public Assessment Report (AusPAR)Enflonsia (clesrovimab) is approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. Enflonsia should be used in accordance with official recommendations.
-
Prescription medicine registrationActive ingredients: pembrolizumab.